CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 311 enrolled
Drug / intervention
Galcanezumabdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02959190
NCT02959190Phase 3Completed
CompareCT.gov

A Phase 3, Long-Term, Open-Label Safety Study of LY2951742 (Galcanezumab) in Japanese Patients With Migraine

Eli Lilly and Company·interventional·Posted Nov 8, 2016·Updated Sep 29, 2020

In Brief

A Phase 3 clinical trial evaluating Galcanezumab for Migraine. Completed, enrolled 311 participants across 44 sites.

Detailed Summary

The main purpose of this study is to evaluate the safety and effectiveness of the study drug known as Galcanezumab in Japanese participants with migraine.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMigraine
CountriesJapan
Collaborators--

Timeline

Phase 3CompletedFinished
2017201820192020202120222023202420252026
First PostedNov 8, 2016
Enrollment StartFeb 7, 2017
Primary CompletionAug 10, 2019
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 9.7 years ago

Interventions

Galcanezumabdrug

Administered SC